Blog

Aakash Desai: Real-World Data on Dabrafenib-Trametinib for BRAF V600E-Mutated NSCLC

Aakash Desai/LinkedIn

Nov 30, 2024, 22:23

Aakash Desai: Real-World Data on Dabrafenib-Trametinib for BRAF V600E-Mutated NSCLC

Aakash Desai, Associate Director and Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on X:

“In Lung Cancer Journal: ‘Real-world data on Dabrafenib-Trametinib (D-T) for BRAF V600E-mutated NSCLC.’ The IFCT-2004 BLaDE study confirms:

Significant efficacy in both pretreated and untreated patients
12-month OS rate: 67.4%
Median PFS: 10.4 months (2L+), 18.2 months (1L)
Toxicity profile: 10.3% discontinuation rate

Early BRAF V600E testing is critical for optimizing therapy.”

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Authors: Aurélie Swalduz, Michèle Beau-Faller, David Planchard, Julien Mazieres, Sophie Bayle-Bleuez, Didier Debieuvre, Vincent Fallet, Margaux Geier, Alexis Cortot, Sébastien Couraud, Catherine Daniel, Charlotte Domblides, Eric Pichon, Elizabeth Fabre, Sébastien Larivé, Ulrike Lerolle, Pascale Tomasini, Marie Wislez, Pascale Missy, Franck Morin, Jean-Bernard Auliac

Aakash Desai: Real-World Data on Dabrafenib-Trametinib for BRAF V600E-Mutated NSCLC

Aakash Desai BRAF V600E cancer Cancer research dabrafenib + trametinib IFCT-2004 BLaDE study Lung cancer lung cancer treatment NSCLC OncoDaily Oncology overall survival progression-free survival real world data

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Richard Sullivan: The State of Global Cancer Surgery from Political and Equity Perspectives

Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More

Radiotherapy for Anus Cancer: Types, Success Rate, Side Effects And More

Special Coverage